viewFrontier IP Group PLC

Frontier IP Group - Elute Intelligence’s AI to back COVID-19 research

RNS Number : 9591H
Frontier IP Group plc
30 March 2020



30 March 2020


Frontier IP Group Plc

("Frontier IP" or the "Group")



Portfolio news - Elute Intelligence uses novel artificial intelligence technology to support scientists researching COVID-19



Frontier IP, a specialist in commercialising intellectual property, notes today's announcement from portfolio company Elute Intelligence Holdings Limited ("Elute") about the launch of a dedicated, free-to-use online COVID-19 Document Reader based on its novel artificial intelligence.

The Document Reader is aimed at supporting scientists researching the disease and related coronaviruses by making it easier and quicker for them to find relevant research. Frontier IP holds a 43 per cent equity stake in Elute.


Elute Intelligence launches dedicated COVID-19 Document Reader to help scientists find vital research more rapidly

Elute Intelligence Holdings ("Elute") today announces it has launched a dedicated free-to-use online COVID-19 Document Reader to help scientists worldwide tackling the disease to find vital research more rapidly.

The COVID-19 Document Reader draws on Elute's novel advanced software tools to intelligently search large and complex databases to identify relevant information swiftly and effectively.  It is available at https://elute.info.

The databases being used include a subset of PubMed, an online resource of more than 30 million citations for papers drawn from Medline, life science journals, books and other sources.  Researchers will be able to search this for articles mentioning terms related to the current COVID-19 outbreak, such as coronavirus, COVID, MERS, or SARS. Elute is proactively working with researchers to identify additional datasets.

Elute's artificial intelligence searches, compares and analyses documents to identify similarities between them by mimicking the way people read. Researchers enter an entire paper already identified as of interest to find other relevant research. They can also create their own documents defining their own interests to enter into the Document Reader to refine searches still further.

This means the approach is very different to conventional keyword or Boolean search technologies.   A patent application has been filed to protect developments of the technology.

Elute is already talking to a number of partners to support and publicise the COVID-19 Document Reader.

Elute was incorporated last year from an existing UK business CFL Software Limited and included complementary intellectual property developed by Frontier IP. Existing customers include the Universities and Colleges Admissions Service ("UCAS") which is using a version of the software called Copycatch to detect plagiarism in students' personal statements. Others include academic institutions, commercial researchers and lawyers.

Peter Fischer, Chief Executive Officer of Elute Intelligence, said: "We are proud to be supporting the global fight against COVID-19 by exploiting our unique capability in document search to support scientists in their crucial research."


Matthew White, Chief Commercialisation Officer of Frontier IP Group, said: "The COVID-19 Document Reader demonstrates just some of Elute's ability to rapidly identify relevant information in unstructured datasets. It is great to see the team deploy this capability in such a short space of time."



Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

[email protected]

Andrew Johnson, Communications and Investor Relations

M: 07464 546 025

Group website: www.frontierip.co.uk

Allenby Capital Limited (Nominated Adviser)

T: 0203 328 5656

Nick Athanas / Nicholas Chambers


ABout frontier IP Group

Frontier IP unites science, finance and industry to build businesses based on outstanding research.  It identifies strong intellectual property and accelerates its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

About RNS Reach announcements

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain.   Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Frontier IP Group PLC

Price: -

Market: AIM
Market Cap: -

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Frontier IP Group teams up with University of Cambridge to tackle gum disease

Frontier IP Group PLC's (LON:FIPP) Neil Crabb discusses with Proactive London's Andrew Scott a new joint project between themselves and the University of Cambridge to tackle gum disease. The study's received a £52,891 grant from the National Biofilms Innovation Centre (NBIC). The...

on 19/6/20

5 min read